je.st
news
Home
› Genzyme And Isis Announce FDA Approval Of KYNAMRO (Mipomersen Sodium) Injection For The Treatment Of Homozygous Familial Hypercholesterolemia
Genzyme And Isis Announce FDA Approval Of KYNAMRO (Mipomersen Sodium) Injection For The Treatment Of Homozygous Familial Hypercholesterolemia
2013-01-29 19:30:00| drugdiscoveryonline News Articles
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMRO (mipomersen sodium) injection
Tags: treatment
approval
injection
announce
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||